A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects
A 26 Week Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Various Doses of HPP404 on Weight Loss in Overweight or Obese Subjects
Sponsor: High Point Pharmaceuticals, LLC.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from High Point Pharmaceuticals, LLC.
More terminations from High Point Pharmaceuticals, LLC.
A PHASE2 clinical study on Obesity and Overweight, this trial is terminated or withdrawn. The trial is conducted by High Point Pharmaceuticals, LLC. and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- High Point Pharmaceuticals, LLC.
For direct contact, visit the study record on ClinicalTrials.gov .